

**Big  Idea**  
**CONNECTpreneur**

**VIRTUAL ROCKET  
PITCH + POWER  
NETWORKING**

**30  
MAY  
11AM - 1PM EDT**

**CONNECTPRENEUR.ORG**

# AGENDA

**11:00 - 11:05 AM**

## VIRTUAL NETWORKING

**11:05 - 11:15 AM**

## WELCOME & INTRODUCTIONS

- TIEN WONG, Founder and Host, CONNECTpreneur Community
- SKYLAR RALLISON, Community Manager, CONNECTpreneur

**11:15 - 12:00 PM**

## ROCKET PITCH SESSION

Companies will be introduced by:

- SARA CLASPER, Associate Attorney, NEXT powered by Shulman Rogers
- MARK HAAS, CEO, AEG

**12:00 - 1:00 PM**

## PRESENTING COMPANY BREAKOUT ROOMS & VIRTUAL NETWORKING

# PRESENTING COMPANIES



**AgTech Logic** - Tom Gauthier



**Flutterpads** - Daniel Ameer



**IPGen** - James Brinkley II

molecular you

**Molecular You** - Jim Kean



**Saltenna** - Dennis Defensor



**SOLution Medical, LLC** - Todd Wallach



**Voyageur Pharmaceuticals** - Brent Willis



**Xero Thera** - David Joseph

# SPEAKERS



## **TIEN WONG, CEO, OPUS8, INC. @tienwong**

Tien is CEO of Opus8, an investment and advisory firm which helps technology companies and alternative investment fund managers raise capital. He is also Chairman of Lumious, a leader in corporate tech training and learning analytics, as well as Chairman of Lore Systems, a provider of network engineering, cloud computing, and strategic IT consulting.

In 1991, Tien co-founded and served as CEO of CyberRep, Inc. until its acquisition in 2003 by Affiliated Computer Services. CyberRep was one of the largest CRM outsourcing companies in the world with over 2,300 employees and \$80 million in revenue. Today, the CyberRep/ACS business unit is one of the world's largest call center operations, with nearly \$3 billion in revenue as divisions of Xerox, Conduent, and Continuum. CyberRep was ranked for 4 consecutive years in INC. Magazine's "Inc. 500" as one of the fastest-growing companies in the USA. CyberRep was profitable for 11 straight years and was backed by Allied Capital Corporation.

Tien is a recognized international expert in CRM, direct marketing, and BPO, having presented at dozens of industry events around the world on CRM and BPO topics. He has provided industry commentary on the ABC, Fox, NBC, CNBC, Maryland Public Television, and China's CCTV networks, as well as Time Magazine, The Washington Post, Inc. Magazine, and Success Magazine. He serves on several boards including the Montgomery County (MD) Economic Development Corp., Center for Innovation Technology GAP Fund's Investment Advisory Board, Junior Achievement, and Refraction. He was appointed by Governor Martin O'Malley to the 9-member Maryland Venture Fund Authority which allocates and manages over \$130 million of capital which is invested into top-tier venture funds and startups. He is an Entrepreneur in Residence at Georgetown University's McDonough School of Business, and a graduate of Dartmouth College.



## **SKYLAR RALLISON, COMMUNITY MANAGER, CONNECTPRENEUR**

Skylar Rallison is a dynamic professional who wears multiple hats as the Community Manager for CONNECTpreneur and Business Analyst for Opus8. She graduated from The Marriott School of Business at Brigham Young University with a degree in Entrepreneurial Management. She has many years of experience in Business Management, Social Media Marketing/Management, Data Analytics, Business Leadership, and Project Management. With a diverse skill set and a passion for facilitating connections and driving business growth, Skylar thrives in the intersection of Community Management and Strategic Analysis.

Skylar enjoys her current role at CONNECTpreneur, which hosts the world's largest monthly investor pitch events as well as 1/2-day Forums with upwards of 900 RSVPs, featuring VIP guests, speakers, exciting presenting companies, and the best CXO to CXO networking on the East Coast. Skylar is pivotal in fostering engagement and building relationships within the investor and entrepreneur community. She creates inclusive digital spaces where members can share insights, collaborate on opportunities, and build a supportive network. Her role includes but is not limited to, team management, event coordination, project management, and marketing.

She also enjoys her current role as a business analyst at Opus8. Opus8 assists companies and fund managers (private equity, VC, and hedge funds) raise private capital from family offices, UHNW individuals, and institutions. Skylar leverages her analytical mindset and attention to detail to provide valuable insights for Opus8. Through her meticulous analysis of investment opportunities and industry research, Skylar helps drive informed decision-making, enabling Opus8 to curate high-quality events that bring together investors and promising ventures.

# EXECUTIVE SUMMARY



**Value Proposition:** AgTechLogic, is a Service-Disabled Veteran Owned Small Business focused on the innovation, creation, and deployment of sustainable and clean technologies that can reduce chemical use up to 90%, making a significant environmental, health, and financial impact on soil and food supply chains. Technology can be applied to existing equipment to benefit agriculture, municipalities, government, railway, and landowners.

**Leadership Team:** Executive team has over 150 years of experience which includes leadership within F100 companies, skills in chemical engineering, artificial intelligence, entrepreneurship, and go-to-market. Advisory Board members have over 30 patents filed, software technology deployment, executive leadership positions, IPO and deep financial expertise and success.

**Challenge:** The world over sprays chemicals in the pursuit to kill weeds and grow crops. Health of humans, soil, crops, and natural resources are in decline due to the abundant use of these chemicals.

**Solution:** AgTechLogic realized that Intelligent Precision Spraying technology along with development of new technologies could provide the capability to reduce the use of chemicals by 90% or greater with the ability to provide data that would lead to a 'continuous loop' that Artificial Intelligence, Machine Learning, and agronomists could leverage to bring future savings and large positive environmental and climate impacts.

**Technology:** Our Technology: Began deploying a unique chlorophyll fluorescence sensor system to retro-fit existing spraying equipment to create an Intelligent Precision Spraying Platform. Then developed our own proprietary hardware to provide additional capabilities accompanied by our own software architecture and mobile web application that allows us to capture data and deliver to any device. This architecture will also allow other sensors, IoT and data to be layered into the application, which makes it unique in the market. In addition, AgTechLogic has begun the development of platforms using robotics and autonomous technology to provide new capabilities. AgTechLogic has also identified areas in technology that were not being developed fully and is now patent pending in the use of virtual reality and artificial reality technology used in agriculture.

**Market:** The global precision spraying marketing was valued at approximately \$2.3 trillion in 2020. The Market is expected to grow at a CAGR of around 11% by 2026. It is also projected for the US to spend nearly \$35.5 billion in 2025 for agriculture weed management. Factors driving market growth include the increased global regulations and mandates for chemical reductions, consumer demand for healthier food, reality of a global food shortage as determined by the United Nations, conservation of water supplies, need to improve water quality, and the demand for climate improvements.

## HEADQUARTERS

1910 S. Stapley Dr.  
Mesa, AZ 95204  
agtechlogic.com  
Established: 9/21

## INDUSTRY

Agriculture,  
Municipality and  
Government

## DOMAIN

Precision  
Technologies,  
Artificial Intelligence,  
Software, Robotics.

## LEADERSHIP TEAM

Founder & CEO:  
Thomas Gauthier


CTO:  
Justin Hoffman

CRO:  
Kevin Richardson

CMO:  
Amy Koenig

VP Operations:  
Erik Barton

Sr. Advisor:  
Chris Wojcik



## Investor Highlights

### VALUE PROPOSITION

*FlutterPads is revolutionizing Extended-Stay rental industry with AI-powered marketplace backed by prime real estate.*

#### COMPANY BACKGROUND

**FlutterPads Inc.** is quietly revolutionizing the Extended-Stay lodging industry by merging AI-driven digital marketplace scalability with the security of company-owned prime real estate. Targeting over \$200B in Extended-Stay rental demand across 25 metro markets, our membership-based model offers quality controlled, fully furnished, flexible-term rentals in prime areas with AI-integrated property screening, dynamic pricing, and a partnership-based ecosystem of home goods and service providers. The company currently owns and operates \$11million in residential properties on the platform.

#### LEADERSHIP TEAM

**Daniel Ameer** – Founder/CEO – *Over \$1 Billion transactions in Real Estate*

**Alexander Veselov** – Co-Founder/Director – *Hospitality for Cruise Liners*

**Braxton Huff** – Director of Tech – *Revamped apps of national brands*

**PRODUCT/SERVICES:** FlutterPads' AI-driven marketplace provides vetted, affordable, flexible term rentals in prime metros, listing its own properties alongside other qualified hosts, ensuring uniform quality standards and dynamic pricing. Actively modulated supply and demand optimizes occupancy rates and prevents intra-network competition, harboring an equitable, sustainable, and quality controlled platform that garners trust and loyalty.

**TECHNICAL/OPERATIONAL ARSENAL:** FlutterPads has a deep background in urban residential real estate development. Combined with AI-driven digital platform, its property management services, and a network of home goods and services vendors offered to platform members, FlutterPads is positioned to be a powerhouse in the Extended-Stay Rental Industry.

**MARKET:** Extended-Stay rental industry is **\$200B** in the initial 25 Markets FlutterPads is targeting. **\$1.25B** is FlutterPad's Obtainable Market Size.

#### DISTRIBUTION CHANNELS:

**Digital Distribution:** *Website & Apps, Social Media*

**Physical Distribution:** *Networking with Region Specific Partners, Events*

**PR & Press:** *Digital & Print publications*

#### COMPETITION:

**OverMoon** – *Funded in 2022 – Vacation Rentals. Owns Assets.*

**Landing** – *Funded in 2021 – Extended Stay with Memberships. Leases Assets.*

**Sonder** – *IPO in 2021 - Extended Stay with Memberships. Leases Assets.*

#### Quick Facts

**Company Name:** **FLUTTERPADS**

#### Contact:

Daniel Ameer

#### Address:

1801 Century Park East, 24Flr  
Los Angeles, CA 90067

**Phone:** (323) 475-7424

**Email:** Info@FlutterPads.com

**Website:** www.FlutterPads.com

#### Industry:

Real Estate, E-Commerce

**Domain:** United States

**Bank:** Bank Of America

**Law Firm:** Presidio Legal, LLP

**Patent Estate:** TBD

**Number of Employees:** 8

#### Leadership Team:

Daniel Ameer

Alexander Veselov

Braxton Huff

Andrew Mezger

Simon Park

**Financing Sought:** \$15 Million

#### Current Investors:

Private Angel: \$1,250,000 Note

Private Angel: \$2,450,000 Note

Private Angel: \$275,000 Equity

#### Use of Funds:

65% - Acquisitions

18% - Operations & Value Adds

17% - Tech, Marketing, Misc

#### Auditor:

#### Financial Projections (Unaudited):

	2022	2023	2024	2025	2026
<b>Revenue</b>	\$1,347,000	2,100,000	\$17,600,000	\$38,500,000	\$59,300,000
<b>EBIT</b>	\$313,000	\$715,000	\$5,200,000	\$14,100,000	\$23,000,000



**Contact:** James L. Brinkley II, Esq.

**Address:** 4709 Harford Rd. #23  
Baltimore, MD 21214

**Phone:** 844-IPGEN-IO

**Email:** info@ipgen.io

**Website:** www.ipgen.io

**Management:**

James Brinkley II, Esq. (Founder & CEO)  
Kevin Denny II (Co-Founder & CTO)

**Industry:** Future of Work / B2B SaaS /  
Legal Tech

**Number of Employees:** Five

**Bank:** PNC Bank

**Law Firm:** Go With Canvas (GwC)

**Amount of Financing Sought:** \$2M;  
Convertible Note/SAFE

**Current Investors:** TEDCO & Angels

**Use of Funds:** Expand Product Dev,  
Reach New Customer Segments, and  
Hire Key Staff

**Company Background:** Led by an IP attorney, IPGen automates and streamlines the entire IP protection process, saving thousands of hours and millions of dollars for those seeking intellectual property protection.

**Management:** James Brinkley II (Founder/CEO), an intellectual property attorney and ex-IBMer, has 10+ years of intellectual property law experience and proven success in the industry. He is a serial entrepreneur and has led companies from small businesses to startups. Kevin Denny II (Co-Founder/CTO), a software and cybersecurity expert, has 15+ years of software development and management experience in the industry. He is a serial entrepreneur, with corporate experience from IBM, Booz Allen Hamilton, and iHeartMedia.

**Products/Services:** IP processes are time consuming and expensive for everyone involved, and entrepreneurs have a lack of knowledge and fear of these processes. Many entities are going unprotected due to lack of capital and lack of knowledge. Every year, millions of IP applications are submitted to IP offices around the world. The time, energy, and cost are well above what it should be.

We are building a community, while providing a self-guided, automated workflow processing platform that allows (1) innovators to easily secure IP; (2) IP experts to better help their clients; (3) entrepreneurs to better navigate their journey; and (4) investors to better source deals and navigate through the due diligence process.

**Technologies/Special Know-how:** IPGen will be covered by a strong IP portfolio, including a couple filed patent applications, more patent filings in our roadmap, and trade secret protection.

**Market:** Our target addressable market includes **any individual or organization that has a need for acquiring intellectual property protection**, including entrepreneurs, startups, accelerators, private equity and venture capital firms, universities and research institutions, law firms, global corporate innovators, and freelancers. IPGen's Total Addressable Market (TAM) is approaching \$100 billion. The U.S. portion of this market is \$20 billion.

IPGen will utilize a multi-level revenue model: (1) Freemium to Premium Tiered SaaS recurring subscriptions based on the level of use and user profile; and (2) Matching/Connection Fees: Entrepreneur to Expert; Entrepreneur to Freelancer; Entrepreneur to Investor.


**Distribution Channels:** IPGen uses a SaaS model to distribute our tools over the Internet, including through strategic channel partners.

**Competition:** Currently, the primary competitors for IPGen's technology are traditional methods that target one aspect of the many IP processes that target one or two of the many customers, while IPGen attacks and covers them all.

**Financial Projections:** (unaudited, in dollars)

	2025	2026	2027	2028
Revenue	1,856,297	16,789,802	32,348,616	63,813,486
EBITA	(2,013,816)	353,553	13,470,707	42,018,242


A molecular-level blood test and AI-powered analytics platform that allows clinicians to access **accurate, predictive insights** into disease risk.



**Problem space / opportunity**

Preventive testing is more important than ever as the lack of early detection costs the industry over a trillion dollars each year. The answers are hidden in the 1m scientific papers published annually, but processing new findings is impossible for a practitioner without sophisticated machine learning tools.

Current diagnostic tests by definition cannot predict disease trends, they can only provide the support practitioners need to diagnose disease. Molecular You is not a diagnostic test, it operates in prevention, prediction, and risk.



**Molecular You (MY) changes the game**

**Accurate prediction**

Biomarker results feed into risk profiles for 26+ health conditions with an average predictive value of 88% and 95% for neurological conditions.

**Scalable**

Our methods are economical, meaning we can increase our testing assay to 800+ biomarker results without impacting operations or cost.

**Preventive**

Over 250 biomarker results delivered per test, comprising quantitative proteomics and metabolomics, the best predictors of disease risk.

Molecular You is a **must have** for clinicians and ACOs delivering early detection of disease, comorbidities, and tracking patient outcomes.

Specialty clinics with unmet needs such as neurology, and value-based care providers stand to benefit the most from improved outcomes and more accurate cost forecasting.

**Raising \$8.5MM seed round, convertible note towards milestones by 2025:**

- Direct channel development, target \$1m ARR
- Formalize partnership and licensing agreement with certified laboratories to process and re-sell MY tests.
- Initiate De Novo Class II software-as-a-device FDA application.
- Continue IP execution and expansion

**Attractive Investment Opportunity**

- **Traction:** Signed customers w/combined 825,000 patient footprint.
- **Strong team:** CEO w/numerous health tech exits and Blue Cross Blue Shield executive experience.
- **Large, attractive market:** Beachhead in clinical neurology, \$660B TAM. \$130MM SOM, identifiable, accessible customers.
- **Reimbursement:** \$1,259/test reimbursement available via existing CPT codes.
- **De-risked platform:** Product operational in Canada since 2015.
- **Capitalization:** \$10MM equity, \$5MM grants
- **Terms:** \$15MM valuation cap, 15% discount. Round close: July 2024.

**Unmatched value proposition - beats the competition**

- Early detection in 26+ health areas
- 250+ protein and metabolite biomarker results.
- Accurate, quantifiable, and reproducible results
- Gives practitioners recommended lifestyle interventions based on data.
- Easy to implement in clinics w/standard phlebotomy practice.
- Simple software portal for practitioners.
- Reimbursable, repeatable testing.



**Jim Kean, CEO**  
jim.kean@molecularyou.com  
+1 503.939.9975




**Rob Fraser, President & CSO**  
rob.fraser@molecularyou.com  
+1 778.227.1721



**Wireless communications are not ubiquitous.  
They are practically unavailable underwater, underground, inside complex urban infrastructures, under jungle canopies, and under the ice.  
WHY DOES THIS MATTER?**

**DOD: Serious threat of a 3-front war in the Middle East, Europe and Indo-Pacific with near-peer advisories and their proxies.  
DOD is supporting innovations and streamlining procurements for AUVs, drone swarms, and AI/ML**




Water surface and underwater AUVs (drones, swarm and AI/ML)



Underground tunnels and mountain bunkers



Urban warfare



Strategic nuclear-armed submarines

**Commercial Industries: Trillion-dollar industries worldwide have unmet needs for wireless communication and sensing.**



Maritime Shipping



Underground mining



Arctic and Antarctic regions  
Potentially



Oil and Gas

**Plasmonics: Tested and Demonstrated Wireless Capabilities:**

**Underwater:** Plasmonics works better than acoustics with faster speed and higher bandwidth. It reaches farther distances and depths versus traditional RF. It doesn't require line-of-sight, unlike optical, or get affected by murky water.

**Underground:** Plasmonics passes through metal walls and limestone (storage facilities).

**Metal and Thick Walls:** Penetrates metal containers, barometric chambers, submarine hulls, pipelines, and shipping containers.

**Complex Infrastructures:** Plasmonics functions through thick walls and doors in warehouses and underground garages.

**Why Saltenna?**

Achieved Technology Readiness Levels (TRLs) 3 to 6 in various applications.

Awarded two patents, with six pending and over 35+ patentable related technologies.

Successfully presented Saltenna's plasmonic technology to DARPA, DTRA, and SOCOM, receiving acclaim from a DARPA reviewer: "The most exciting development in the electromagnetic spectrum in 60 years."

Anticipates securing two DoD R&D awards totaling over \$6.8\_+ million to enhance plasmonic range, depth, and capabilities.

**Saltenna Seeks \$2 Million Seed Funding:**

- Secure Saltenna's plasmonic IP through a comprehensive patent strategy.
- Enhance plasmonic range, depth, and capabilities across all domains.
- Develop first wave of DOD and commercial product lines.

**Saltenna Team**

**Dendy Young, Chairman of the Board, Founder**

B.S. in Electrical Engineering and Computer Science, Massachusetts Institute of Technology. M.B.A. from Harvard Business School.  
*LinkedIn:* <https://www.linkedin.com/in/dendyyoung/>

**Dennis G. Defensor, Chief Executive Officer**

B.S. in Biology, Beloit College. J.D. from the Catholic University of America – Columbus School of Law.  
*LinkedIn:* <https://www.linkedin.com/in/dennis-defensor-a48160/>

**Dr. Igor Smolyaninov, Ph.D., Chief Technology Officer and Founder**

M.Sc. Moscow Institute of Physics and Technology. Ph.D. in Physics, Kapitza Institute for Physical Problems, Russian Academy of Sciences.  
*LinkedIn:* <https://www.linkedin.com/in/igor-smolyaninov-2725b212/>

**Dr. Quirino Balzano, Ph.D., Senior Scientist**

Ph.D. Electronics Engineering. University of Rome, La Sapienza, Rome, Italy.  
*LinkedIn:* <https://www.linkedin.com/in/quirino-balzano-a04bb617/>

**CAPT Denny Brisley, USN (Ret.), Chief Strategy Officer**

B.A. International Relations, Stanford University. M.A. Defense and Strategic Studies, U.S. Naval War College.  
*LinkedIn:* <https://www.linkedin.com/in/dennybrisley/>

**Sanjee Singla, Vice President of Product Development and Operations**

B.A. in Economics and Physics, Stanford University. M.S. Management Science and Engineering w/concentration in Global Project Finance, Stanford University. CAPM, Project Management Institute.  
*LinkedIn:* <https://www.linkedin.com/in/sanjeesingla/>

**CONTACT:**  
Dennis Defensor, CEO  
[dennis.defensor@saltenna.com](mailto:dennis.defensor@saltenna.com)  
703-409-9136

**Value Proposition:** SOLution Medical is a specialty pharmaceutical company focusing on drugs requiring mixing at the point of care.

**Company Background:** SOLution Medical is a specialty pharmaceutical company focusing on drugs requiring mixing at the point of care. SOLution was founded to tackle the unmet market need of adrenal crisis treatment by streamlining the current complex 14-step process unsuitable for self-use in emergencies. Over 200,000 patients in the US, representing a \$320M addressable market, experience these emergencies requiring immediate administration of the stress hormone cortisol by means of a 14-step complicated process while in a state of severe physical and mental impairment. We are launching our first easy to use 3-step drug product for Adrenal Crisis in 2026, representing an epi-pen like market need targeting \$145M in US sales. Our proprietary drug/device injector platform offers expanded product and revenue opportunities via our direct drug pipeline and external collaborations.

**Leadership Team:** Having developed and marketed drugs and medical devices for pharma companies like Pfizer, Teva, Lilly, Roche, J&J, Amicus, and Bayer, SOLution’s experienced management team and advisors bring practical and strategic insight drawn from international business development transactions including financings, strategic partnerships, M&A, manufacturing, supply chain and distribution, and intellectual property. The Company’s CEO has experience commercializing 7 analogous drug products globally and helped to provide 2 lucrative pharmaceutical company exits greater than 10X each.

**Products/Services:** SOLution has developed two easy-to-use products for adrenal crisis treatment and for future drug pipeline expansion. The pre-filled syringe for adrenal crisis is anticipated to launch into the retail (i.e. prescription) and institutional (i.e. hospital) markets in 2026, followed by the retail launch of the TwistJECT™ autoinjector in 2027/28. Both products can accommodate powder/liquid or liquid/liquid configurations and are customizable for multiple routes of administration and therapeutic applications.

**Technologies/Special Know-How:** SOLution is a pharmaceutical company supplying combination drugs and device products. We have built a large intellectual property portfolio, including 6 patent families consisting of device utility and design, drug formulation, drug fill-finish, and packaging, and multiple trademarks and trade secrets. Additionally, our key value creation driver is our proprietary direct end-to-end supply chain via our strategic partners.

**Market:** The company forecasts \$145M in U.S. sales with ex-US and pipeline expansion upside. Revenue is based on net pricing after discounts/distribution with 85% gross margin for both products. SOLution anticipates Tier 3 reimbursement with full patient access, no prior authorization, and no step through treatment at product launch based on feedback from payers. Pricing and reimbursement are triangulated around 1) historical product sales data, 2) coverage, coding, and payment assessment, and 3) real-world patient data.

**Distribution Channels:** Our initial go-to-market strategy will be via market "pull" from patients, clinicians, and advocacy groups. We will also have a sales force to “push” growth and usage in both retail and institutional markets, and will partner Ex-US with strategic players in key geographies. Additionally, we will develop applications with partners to expand usage and drive business development.

**Competition:** SOLution's product lineup offers distinct advantages compared to current reconstituting vials, ampules, pre-filled syringes, and auto-injectors by addressing drug formulation, drug fill-finish, reconstitution and product manufacturing limitations faced by competitors. Competitors also have less user-friendly designs and limited market potential. With our easy-to-use products, SOLution aims to enhance treatment adherence, satisfaction, and overall management effectiveness.

**Quick Facts**

**Company Name:** SOLution Medical

**Contact:** Todd Wallach, CEO

**Address:** Philadelphia, PA

**Phone:** 215-896-7001

**Email:** todd@solutionmedco.com

**Website:** <https://www.solutionmedco.com/>

**Industry:** Specialty Pharma | Drug Delivery | Combination Products

**Initial Market:** Adrenal Crisis Treatment

**Bank:** JPMorgan

**Law Firm:** Goodwin

**Patent Estate:** Troutman Pepper

**Number of Employees:** 5

**Leadership Team:**

Todd Wallach, Chief Executive Officer  
Julia Anthony, Founder & Chief Strategy Officer

David Palling, VP CMC & Supply Chain  
Mikael Avery, VP Innovation & Design  
Simon Rogers, VP Brand Strategy & Mktg

**Amount of Financing Sought:** \$5M

**Current Investors:** Series A Participating Preferred Round led by Keiretsu Forum Keiretsu, Band of Angels, Ten Capital, and Golden Seeds are all syndicating in the round. Existing investors include Ben Franklin Technology Partners, NextFab, Strategic Partners and HNW/Angels.

**Use of Funds:** Pre-filled Syringe Manufacturing Readiness in 2025

**Auditor:** Stefano Slack

**Financial Projections (Unaudited):**

(dollars in thousands)	2026	2027	2028	2029	2030
Revenue	\$8,722	\$27,879	\$76,138	\$140,798	\$147,494
EBIT	(\$5,825)	\$4,770	\$33,628	\$81,646	\$89,126

**Problem:**

- Global shortage of natural pharmaceutical grade barium, and iodine, required for radiology contrast media/ drugs
- Expensive less performant synthetic barium contrast agents being produced
- Adverse Effects associated with current radiology contrast media/ drugs
- Poor image quality
- Supply chain issues compounded by geo-political instability

**Solution:**

- Vertically integrate in all aspects of the radiology drug market
- NEW Carbon drug development from carbon capture
- Voyageur owns rare natural pharmaceutical grade barium source at Frances Creek (FC), British Columbia, Canada; Iodine resources in Utah and Oklahoma; and has advanced carbon fullerene drug development partnership with an Alberta based R&D firm
- 5 barium products approved by Health Canada (HC), in production, and launched in Canada and other non - US and non-European countries using third party contract manufacturer and synthetic barium
- Initially using foreign imported barium and iodine API, for 3<sup>rd</sup> party manufacturing and transition to Voyageur’s own pharmaceutical manufacturing facility
- FDA approval process in progress (12 months), followed by EMA in Europe
- Acquire pharmaceutical facility and equipment to manufacture radiology drug products
- FC production available to displace foreign barium, increase drug performance and reduce costs (18 months)
- Develop US source of iodine production with future financing and internal cash flow (3 years)

**Market:**

- Global radiology contrast drug market of \$6.2 billion: \$12.4 billion in 10 years
- Our objective is 8% of the \$600 million barium market within 3 years, over 5 years, Voyageur targets capturing 4% of the global market for barium and iodine
- Fullerene drug development for advanced contrast agents may be very disruptive with introduction of new innovative higher performing and safer drugs
- GE Healthcare projects a significant market doubling in the next decade due to rising chronic disease throughout the global population

**Competition:**

- Voyageur Pharmaceuticals is poised to disrupt the monopolized barium contrast market
- Voyageur owns critical resources, ensuring cost efficiency and superior product quality. This strategic advantage positions Voyageur to challenge industry leaders and capture significant market share

**Carbon Capture - True ESG:**

- Carbon Capture system for manufacturing
- Carbon Farming est. start-up revenue \$10M USD / year
- New Fullerene drug development from CO<sub>2</sub>

**\*\*\* \$1.9M USD – Sales and Distribution Contract Signed May 24, 2024 \*\*\***

**Quick Facts**

**Company Name:** Voyageur Pharmaceuticals Ltd. (TSX-V: VM)  
**Contact:** Brent Willis, CEO  
**Phone:** 1.403.923.5944  
**Email:** brent@vpharma.ca  
**Website:** www.voyageurpharmaceuticals.ca

**Industry:** Pharmaceutical Manufacturing  
**Bank:** CIBC  
**Law Firm:** DS Lawyers Canada LLP  
**Number of Employees:** 4  
**Number Consultants:** 30  
**Amount of Financing Sought:** \$25M USD  
**Current Investors:**

- Public
- Leede Jones Gable
- PI Financial Corp.

**Use of Funds:**

- FDA Licensing
- Sales and Marketing
- Pharmaceutical Facility Acquisition
- Pre-clinical Fullerene Drug Dvlp.

**Auditor:** MNP LLP  
**Leadership Team:**  
 Brent Willis, Founder, CEO
 

- CEO, Voyageur Industrial Minerals Ltd
- President, Tiger Ridge Resources Ltd

 Brad Willis, Founder, COO
 

- COO, Voyageur Industrial Minerals Ltd
- COO, Tiger Ridge Resources Ltd

 Albert Deslauriers, CFO
 

- VP Finance Lafarge Canada

**IP/ Technologies Special Know-How:**

- Health Canada Licences
- IP – Advancing FDA 505(b)(2) barium drug pathway
- IP - Advance Fullerene Carbon Drugs in development
- Revenue Generating Carbon Capture Rain Cage Eden System
- Mineral Assets: barium, iodine, carbon, lithium, and battery metals

**Financial Projections In 000\$ USD**

	2024	2025	2026	2027	2028
<b>Revenue</b>	\$ 100	\$ 10,000	\$ 62,000	\$ 168,000	\$ 272,000
<b>EBIT</b>	\$ (4,000)	\$ (2,000)	\$ 25,000	\$ 68,000	\$ 108,000



## XEROTHERA EXECUTIVE SUMMARY

XeroThera- HQ, Philadelphia, world leader in nanostructured biomaterials. Founded by Univ of Penn Prof. Paul Duchene → renowned authority on nanostructure biomaterials and bone formation led by experienced team that built Orthovita to IPO and sale to Stryker for \$316M. We have developed breakthrough nanostructured materials platform – strong patent portfolio bioceramic powders derived from sol-gel science. We have outstanding pre-clinical data that is predicable of successful clinical safety and efficacy. Targeted, sustained release of therapeutics. The TAM in orthopedics for prevention and treatment of surgical site infections in the US is \$6.8B.\*

**Problem:** Surgical Site Infections (SSI's) a leading cause of death – 5-year mortality rate higher than breast cancer, melanoma, Hodgkin's, and many other cancers - *Rezapoor & Parvizi (2015)*

**Solution:** XeroThera has the world's only bone graft substitute with *sustained* antibiotic release → hours, days, weeks, months inhibits post-surgical infections. **Current stand has the surgeon apply in a single burst antibiotic dose prior to closing the surgical site. It is done prophylactically in all surgeries, unregulated and ineffective.** Surgical site infections range for 2% to 50%.

Our pipeline also includes *sustained release injectables, coatings, and targeted therapies.*

With low-risk regulatory path, our capital requirement of \$6M to FDA market clearance and commercialization provides an early exit in 2026/early 2007. We are on track for this June 2024 FDA Market Clearance of sustained release drug-carrying biomaterial (XeroSyn). Predicate 510(k) for antibiotic-loaded products, 25-patient study → pivotal study results in trauma surgery by 4Q2025.

We have raised \$500,000 of a \$1million bridge note (Terms: \$20% discount, 5% interest rate and a \$10M Cap, Units of \$50,000).

We are currently in due diligence with two major orthopedic companies interested in a strategic alliance that can include both equity and non-dilutive fee-generating agreement. We are also in earlier discussions with two additional leading orthopedic companies, as well. This additional \$500K note will provide enough runway to finalize a corporate deal and/or an equity financing round. We believe a \$6 million Series A round or non-dilutive corporate strategic investment will be sufficient for our first FDA approval 2 plus years and an early exit opportunity.

Let by an experienced life science team with over 150 years of biomaterials and orthopedic experience.

**Paul Ducheyne, Ph.D.**, XeroThera Founder, Chairman, and CEO

Founder and former Chairman of Orthovita. Consultant to leading orthopedic companies for 30 years. Prof Emeritus, University of Pennsylvania, Biomaterials research.

**David S. Joseph, MBA**, President, and Director

former President and CEO of Orthovita. Forty-five years of life science experience as co-founder and CEO of five companies in medical devices, biomaterials, diagnostics, and pharmaceutical companies including two IPO and two M&A exits.

**Charles S. Cohen, Ph.D.**, Vice President, Product Development

Former Director of Product Development at Orthovita and VP Product Development at Gentis.

**Sanjib Bhattacharyya, Ph.D.**, Vice President, Research and Development

Cambridge University, CNRS (Orléans, France) University of Pennsylvania

**Noel Rolon**, Vice President, Clinical Affairs

30+ years industry experience, including leading clinical, R&D and quality roles at X-Biomedical, Inovio, J&J.

Why is this a compelling investment opportunity? Rarely does a medical device company with a small capital investment have a high growth potential to that of a pharmaceutical company. Because we have outstanding science and preclinical data, low regulatory risk drug-device combination product via 510k regulatory pathway, 92% gross margin products delivering commonly used inexpensive antibiotic paired with low-cost biomaterial bone void fillers, used prophylactically in almost every surgery equals pharma like revenue growth, patents, a deep pipe and an experience management team.

For Convertible Note Term Sheet and Not Documents

Contact:

David S Joseph

President

[joseph@XeroTheraInc.com](mailto:joseph@XeroTheraInc.com)

m. 484 459 5076

[www.xeroThera.com](http://www.xeroThera.com)

# PARTNERS



## **NEXT powered by SHULMAN ROGERS**

NEXT disrupts the legacy legal industry by offering a broad range of fixed fee solutions (stand-alone products and annual legal plans) delivered by senior attorneys with valuable business expertise. NEXT solves the problem that startup and emerging growth companies face when launching their business as well as scaling: lack of access to predictable legal fees, seasoned attorneys, the latest technology and key business services. We use cutting edge technology platforms to deliver real efficiencies, transparency and a collaborative environment for clients, attorneys and investors. NEXT partners with its clients to de-risk their business and get to the NEXT level, together reaching each milestone of success. NEXT is powered by Shulman Rogers, a full-service law firm with nearly 100 attorneys offering superior service across a wide range of practice areas. The firm also offers robust personal services such as residential closings and trust and estate planning. Shulman Rogers has earned its reputation for providing quality representation, business insight and client value, serving as a highly attractive alternative to larger, higher-priced firms and smaller, less diverse firms. Learn more at [ShulmanRogers.com](http://ShulmanRogers.com).

## **ANTHONY MILLIN, NEXT CHAIR & PARTNER, SHULMAN, ROGERS**

Anthony Millin is the Chair of NEXT and a trusted legal and business advisor to startup, early-stage, and emerging growth companies. As a corporate and securities attorney, a successful serial entrepreneur, and a venture capitalist, Anthony brings a unique legal and business perspective to advising his clients. Anthony understands firsthand what it takes to start, scale and manage a company, to successfully prepare for and run a fund-raising process, and to address the legal issues faced by a startup. Another specialized skill set Anthony brings to the table is his China-based experience, assisting early-stage and middle-market companies interested in conducting business in China or seeking direct foreign investment from China. Anthony also serves as a Venture Partner at Urban Us, a seed-stage VC firm. Contact Anthony at [amillin@shulmanrogers.com](mailto:amillin@shulmanrogers.com).

## **AEG @enterpriseGrowth**

AEG is a growing and profitable company that provides elite business advisors and midmarket CEOs unprecedented business development and peer-to-peer networking opportunities through an ecosystem of city-based communities. Deliberate culture and technology create deep personal relationships to drive fast and efficient business referrals that accelerate business development and growth for these advisors and CEO peer groups.

## **MARK HAAS, CEO, AEG @MarkHaas**

Mark Haas is Co-founder and CEO of AEG (Association for Enterprise Growth), responsible for strategy, operations, and expansion of its communities to 30 cities nationally. He was previously President of ROM a strategy and operations management consulting firm, advising CEOs and boards to include leadership training for Tanzanian energy executives, developing curricula to train consultants in 40 countries for an international bank, crafting strategy and innovative business models for \$120 million nonprofit, merging two scientific associations, re-organizing a biomedical research agency, facilitating development of WWIV military strategy, and of facilitating a global R&D strategy for the US Navy.

## **PRINCE WILLIAM COUNTY DEPARTMENT OF ECONOMIC DEVELOPMENT**

The Prince William County Department of Economic Development and Tourism works hard to create a pro-business, globally-competitive environment that generates new, high-quality, and sustainable job opportunities for our residents and destination-driven attractions for our visitors. The department engages in a broad portfolio of services, partnerships, and strategic alliances to benefit the business community, including small businesses, startups, and entrepreneurs.



# PARTNERS



## **MICHELE WEATHERLY, DIRECTOR OF EXISTING BUSINESS AND ENTREPRENEURSHIP, PRINCE WILLIAM COUNTY**

Michele Weatherly currently serves as the Director of Existing Business and Entrepreneurship with Prince William County Department of Economic Development and Tourism. Michele is a Washington DC Metro area Business Development professional with a track record of successful leadership in trade associations and economic development. Michele specializes in workforce and business development programs and marketing with a strong network of industry colleagues in the DC metro region and beyond the beltway.

Michele currently serves on the Board of Directors for Virginia Career Works, Committee for Dulles, Virginia Serious Game Institute, and the Career Technical Education Program Advisory Council for Prince William County Schools.



## **REFRACTION @refractionpt**

Refraction is a leading nonprofit innovation hub in Northern Virginia, that provides mentoring, programs, and office space for startups and high-growth companies to help create jobs in the greater Washington region. In five years, more than 300 member companies have collectively raised over \$350 million in capital. Refraction's partners include Amazon, Cox, Dominion Energy, MITRE, Fairfax County, Arlington County, Loudoun County, Virginia Innovation Partnership Corporation, and Virginia Tech.



## **DINGMAN CENTER FOR ENTREPRENEURSHIP, UNIVERSITY OF MARYLAND @UMD\_Dingman**

The Dingman Center for Entrepreneurship is a top-tier entrepreneurial institute recognized around the world as a leader in enterprise creation. The Dingman Center is continuously pushing the boundaries of teaching and learning with its focus on practical entrepreneurship, global innovation, and international classroom experiences. The Center promotes opportunities that provide maximum resources to start-up businesses in terms of ideation, execution, and financing; and that support its mission to take entrepreneurs "from the back of a napkin to the first \$1 million in financing."



## **KEIRETSU FORUM @KeiretsuAngels**

Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists, and corporate/institutional investors. Keiretsu Forum was founded in the San Francisco East Bay in California in 2000 by Randy Williams. Keiretsu Forum is a worldwide network of capital, resources, and deal flow with 53 chapters on 3 continents. Keiretsu Forum members invest in high-quality, diverse investment opportunities.



## **FITCI - FREDERICK INNOVATIVE TECHNOLOGY CENTER, INC @FITCInc**

The Frederick Innovative Technology Center, Inc. (FITCI) is a business incubator and accelerator designed to cultivate entrepreneurship in Frederick, Maryland. FITCI specializes in the strategic business support of local entrepreneurs in the early stages of mostly science and technology-based businesses: Biotechnology, Information Technology, Renewable Energy, and Cyber Security. FITCI currently has two locations in Fredrick, MD, and 52 client companies.



## **THE BALTIMORE ANGELS @baltimoreangels**

The Baltimore Angels is an angel investor group based in Baltimore, MD. Founded in 2009, its mission is to invest profitably in the regional entrepreneurial ecosystem and advance early-stage innovators to the next stage of capital formation. Its vision is to be the most trusted resource for angel capital investment and entrepreneurial mentorship in the Greater Baltimore region. A new generation of angel investing comes to Baltimore. If you are a tech entrepreneur or community-minded investor, please be in touch with Baltimore Angels. This is not your father's (or your uncle's) investment group.

# PARTNERS



## MARYLAND TECH COUNCIL VENTURE MENTORING SERVICES

The Maryland Tech Council Venture Mentoring Services (MTC VMS) program is one of the leading team mentoring services available in the state of Maryland that is both highly sophisticated and results-driven. It exists to foster an environment that encourages innovation while expanding financial and business opportunities for tech, cyber, and life science start-ups. The MTC VMS Program provides free team-based mentoring services to qualified Maryland-based tech and life science venture CEOs who are accepted into the program. Since the MTC VMS program began, more than 75 ventures have enrolled & \$100MM has been raised in capital & grants.



## STARTUP GRIND-COLUMBIA, MD eStartupGrindDC

Startup Grind-Columbia, mid-Maryland Chapter is part of the largest global community for innovation, entrepreneurship, and the startup community. We're actively educating, inspiring, and connecting more than 2MM+entrepreneurs, 600+ cities, and 130+ countries. We nurture startup ecosystems through mentorship, advisory services, education, inspiration, access to capital, and most importantly, connecting members with the resources we need to have the best opportunity to grow phenomenally successful ventures.



## ANGELS + LIFE.SCI INVESTORS

Formed in 1996, the Angels + Life.Sci Investors Network is organized under NJAngels.net. We are a manager-led, loosely organized network of investors and accredited Angels, Coaches, and Experts who Sponsor world-class Entrepreneurs. Our colleagues have deep experience and technical domain expertise in all of the life sciences disciplines in which we are involved, including nanobio tools, materials, and devices: tele-diagnostics, augmented healthcare & remote patient monitoring, automation and robotics, & advanced chemistry for drug discovery.



## GEORGETOWN ENTREPRENEURSHIP INITIATIVE

Entrepreneurship is one of the world's most powerful forces for positive change. Georgetown Entrepreneurship seeks to instill an entrepreneurial mindset in students, foster an entrepreneurial culture across the university, support the successful growth of alumni ventures, and leverage the power of entrepreneurship to make an impact in the world beyond Georgetown.



## JEFF REID, FOUNDING DIRECTOR, GEORGETOWN ENTREPRENEURSHIP INITIATIVE, GEORGETOWN UNIVERSITY'S MCDONOUGH SCHOOL OF BUSINESS eHoyapreneur

Jeff Reid is the Founding Director of the Georgetown Entrepreneurship Initiative and Professor of the Practice of Entrepreneurship at Georgetown University's McDonough School of Business. Reid is a catalyst for entrepreneurship and a well-known leader in entrepreneurship education. In 2009, Reid launched the Georgetown Entrepreneurship Initiative to catalyze entrepreneurial thinking and activities across Georgetown University and impact the growing DMV startup community.



## RYAN & WETMORE, P.C. eRyanWetmorePC

Ryan & Wetmore is a full-service accounting and management consulting firm, servicing the Northeast/ Mid-Atlantic region since 1988. What makes us different from other accounting firms is our proactive approach. We work hard to earn our clients' confidence by encouraging open communication year-round. This approach has enabled us to help clients become more efficient, more competitive, and more profitable. Through our numerous management engagements, we have become trusted, unbiased advisors.

# PARTNERS



## **PETE RYAN, CO-FOUNDER & PARTNER, RYAN & WETMORE**

Pete co-founded Ryan & Wetmore in 1988, a 3 office, 35-person firm serving the Mid-Atlantic region. He currently works with clients to address tax, audit, and accounting issues. He also has significant experience in international tax matters and business consulting services. His expertise extends to Healthcare organizations, Construction and Real Estate, Government contractors, Technology, Manufacturing, and High Net Worth Individuals. Pete has served on the Board of Directors for several organizations. He is an active member of the Healthcare Advisors Association, the Real Estate and Construction Association, the CPA Manufacturing Services Association, the Virginia Transportation Construction Alliance, and the Construction Financial Management Association.



## **ENTERPRISE TRANSFORMATION SOLUTIONS**

### **INES LEBOW, FOUNDER AND PRINCIPAL @ilebow1**

Ines LeBow is the Founder and Principal Startup Consultant at Enterprise Transformation Solutions (ETS), which advises entrepreneurs on how to position themselves for funding. Over the course of her 30+ years in the industry, Ines has helped companies secure more than \$800M in funding, led start-ups and turnarounds for companies with up to \$500M in revenue, managed 11 M&A transactions, and guided 9 companies to a successful exit. With expertise spanning Operations, Executive Leadership, and Mentoring, Turnarounds, Revenue implementation, Engineering, as well as Communications, Ines has helped many companies prepare for VC and angel investment.





## May 30 Attendees As of 05 30 24

SPEAKERS			
First Name	Last Name	Title	Company
Tien	Wong	Founder and Host	CONNECTpreneur
Mark	Haas	CEO	AEG
Sara	Clasper	Associate	NEXT, Powered by Shulman Rogers
PRESENTERS			
First Name	Last Name	Title	Company
Tom	Gauthier	Founder & CEO	<b>AgTech Logic</b>
Daniel	Ameer	Founder & CEO	<b>FlutterPads</b>
James	Brinkley II, Esq.	Founder & CEO	<b>IPGen</b>
Jim	Kean	CEO	<b>Molecular You</b>
Dennis	Defensor	CEO	<b>SALTENNA</b>
Todd	Wallach	CEO	<b>SOLUtion Medical, LLC</b>
Brent	Willis	CEO	<b>Voyageur Pharmaceuticals</b>
David	Joseph	President	<b>Xero Thera</b>
ATTENDEES			
First Name	Last Name	Title	Company
Yousif	Abood	Founder	SocialWeaver
Carli	Abram	Founder	Pollynation Apothecary
Michael	Adler	Managing Partner	Law Office of Michael E. Adler
Kanav	Aggarwal	Founder	Karivax
Sedegan	AIME	Engineer Hydraulic Water Expert	Embassy of Kingdom of Netherlands
Derek	Akner	Business Development	Surge PE
Ahmed	Alhaimi	Student Analyst	Sorenson Impact
Cliff	Anders	President	LeoSat Enterprises
Jolene	Anderson	Managing Director	VectorPoint Ventures, LLC
Sheryl	Anjanette	CEO	Parsley360
Lekan	Anlugbua II	CEO	Leks Energy LLC
Suresh	Annappindi	Founder and CEO	XOOM FOODS
Christopher	Antonopoulos	CEO	Measured Results Marketing
Paul	Armijo	President & CEO	Armijo Innovations LLC
Calvin	Arterberry	CEO	Midnight Run
AJ	Attavar	Angel Investor	NPS, Inc
Marco	Ávila	President/CEO	MD Hispanic Chamber of Commerce
Kokoro	Azharul	Junior Analyst	The Westly Group
Albert	Baldwin	Founder/CEO	Alfa Omega Grafx
Dan	Ballin	Chief Executive	Ideas Crucible
Ben	Bamberger	COO	Tiber Solutions
Justin	Banford	Attorney	Bean, Kinney & Korman
Carlos	Baradello	GP & Professor	Alaya Capital Partners
SJ	Barakony	Super Connector	
Jon	Barlow	EcoProjects Manager	Power Alternative LLC
Daniel	Barth	Principal	Yamaha Motor Ventures
Thomas	Bascom	President	LinkSpace, LLC
Kyle	Bayliss	Managing Director, Corridor Region	Maryland Small Business Development Center
Jim	Beals	COO	CoolWaters Technology
Jay	Beam	Managing Director	Adasel Global Partners LLC
Martiel	Beatty	CEO	MB Branding Solutions
Michael	Beaubaire	Principal	Beaubaire LLC
Melanie	Beldock	Founder	Logan Group Consulting
Steffi	Besselink	European Lawyer in Data Protection and Contracts	Quarto Compliance
Nilesh	Bib	Volunteer	Aar solutions
Mohammed Ashiq	Bin Nizam	Finance	
Colin	Blair	Co-Founder	Sensurance
Jose	Bolanos MD	CEO	Nimbus-T Global inc
Larry	Boodin	Business Development Director	Thompson Financial
Prasad	Bopardikar	Principal	
Swapnil	Bora	CEO	MeshTek Labs
Jan	Breukers	CEO	First Choice Bio, Inc.
John	Brinkhurst	CCO	AgriGreenTech Ltd
James	Brinkley	Founder & CEO	IPGen
Denny	Brisley	Chief Strategy Officer	Saltenna
Ben	Broedel	President & CEO	Athena Enzyme Systems
John	Brooks	Chair	Alertgy
Doug	Brown	Principal	DAB Holdings LLC
Dwika	Budhyantara	Founder	Hata
Patrick	Burke	Dir. Business Development	Amarex Clinical Research
Wade	Byrd	Founder / CEO	QEPR
Mary	Ca	Investor	Investmenty

Alexius	Cabral	Cofounder	SD Holdings
Anthony	Cammarata	Outsourced CFO	Startupcannon
Shannon	Campbell	VP, Medical & Clinical Affairs	Optina Diagnostics
Mike	Candela	VP Growth	Measured Results Marketing
Aldrin Jay	Cardona	Sales Associate	Management Analytics
Christian	Carello	Founder, CEO, + Angel Investor	Envisionit Consulting, LLC
Joe	Carlin	Principal	JonXeone Capital
Sue	Carr	President	CarrTech Corp
Hepzel	Castro	Independent IP Consultant	HCH Consulting
Daniele Domenico	Celsa	Community Manager	Coderblock
Faith	Chacko Abraham	Chief Executive Officer	Volshauz Brands Pvt Ltd
Hubert	Chan	Founder	Helppo SaaS
Nelson Hyde	Chick	CAO	Foil Flyer
Kyle	Christopher	Founder	MRG Health - SmartCare360
Angela	Clark	Ed	A Best Choice Mobile Ultrasound & Pregnancy Resource Center
Natalie	Clyke	Founder   CEO	Rocktree MgO Construction Materials Inc
Melroy	Coelho	CMO	RexEMR
Scott	Collins	CEO	Austin Innovation Group
Brendan	Corcoran	CTO	Tiber Solutions
Aidan	Courtney	Chairman	VascVersa Ltd
Dayna	Cousino	MLO	Revolution Mortgage
McLean	Cozine	Co-Founder	Conquiro
Roger	Cresswell	Sr. Consultant	AgTech Logic
Albert	Crews	VP of Product Innovation	St Jude
Lubna	Dajani	CEO	Allternet
Adam	Dakes	Investment Analyst	GoGetta
Jennifer	Dalton	Founder	BrandMirror
Niem	Dang	Founder/ Principal Consultant	Four Winds Solutions LLC
Darren	Dasburg	CEO	Clarus Biologics
Jarosl�w	Dastyh	CEO	Proteon Pharmaceuticals
Chetna	Daswani	Project Manager	Wiggles
Anthony	Davis	Founder & Chairman	Top Tier Producers LLC
Roel	De Alejandro	Consultant	Freelance Consultant
Davide	De Lucrezia	CEO	Officinae Bio
Hank	Dearden	Principal	Group 3D
Paramita	Debbarman	Business Consultant	PDCC
Sahil	Dedhiya	Investment Strategiest	Money Lancer
Derek	Def	Marketing	Government IT
Chelsea	Derbin	Sales Development Rep	CBIZ
Shantanu	Dev	CEO	Examd
Lillian	Diaz	Personal Trainer	Wellness Peak Nutrition L.L.C.
Sujit	Dike	CEO	Gyder surgical
John	Dinusson	President	Wave Forms Med Tech
Lari	Dkhar	Senior Investment Analyst	NZGCP
Thomas	Douthitt	CEO	Caeli Vascular Inc.
Greg	Downey	Managing Director	Purim Ventures
Mike	Doyle	Managing Director	Goldin Ventures
Lee	Dudka	Board Director	Throne Bio
Raviprakash	Dugyala	Private Investor	RD Capital
Gib	Dunham	Founder	ACTA Thermal Technologies
Radha	Duttgupta	VP, Clinical	Nucleix
Cherie	Edilson	Founder/CEO	Member Marketplace, Inc.
Altan	Er	P.M	Mosaic D&C
Maria	Ermolova	Managing Director	Weild & Co.
Monica	Errico	Managing Director	UNited BioChannels
Maxwell	Erskine	Accountant	Saltenna LLC
Pablo	Espada	Consultant	dataforgex
Idong	Essiet-Gibson	Principal	The Idyeas Group
Jason	Ettinger	Consultant	JME
Sandy	Eulitt	President	Galaxia, Inc.
Matt	Evans	Mentor	SCORE
Herb	Ezrin	CEO & President	Potomac Business Group
Farbod	Fakhrai	CEO	Com-Sec
Branda	Fan	Founder	Nowy
Arshad	Farooqi	Founder	mobrisehealth inc
Afrina	Fatini	Personal Interest	Personal Interest
Christopher	Feia	Director of Private Equity	ZT Corporate
Benito	Fernandez	CTO & Co-Founder	The Whisper Company
Emmett	Ferra	COO	IKIGAI International
Veronica	Fey	Operations and Analysis	SoundBoard Venture Fund
Siri	Fiske	Founder	Mysa School & Microschools Network
Ana	Florescu	Co-Founder & COO	In Diagnostics
David	Fogel	Managing Director	Swifton CFOs LLC
Yannick	Fokou	Founder	FOKOUTECH AND VERODAV GROUP
Cindy	Fraley	Membership Director	Keiretsu Forum Southern California
Sue	Frank	Self-Employed	Think Makeup!
Rob	Fraser	CSO	Molecular You

Daniela	Fried	Project Manager	Creative PM Consulting
David	Friedrichs	Co-Founder & Co-CEO	Cerqular Inc.
Sathish Kumar	G	Partner	SBSs & Associates
William	Galle	Principal	DPS
Julie	Gerber	CEO and Co-Founder	Meloscene
Daniel	Geselowitz	Patent Agent	Kratz, Quintos & Hanson, LLP
Gregory	Giammittorio	Partner	Potomac Law Group PLLC
Rick	Gilchrist	CEO & Founder	Vannadium
Jeff	Gillani	Board Member	Syncaru
Kaija	Gisolfi-McCready	Senior Analyst	Paladin Capital Group
David	Gladstone	CEO	gladstonecompanies
Andrew	Goetzinger	Partner	Mulbah Media
Eli	Gorovici	CEO	Piont.AI
Yuying	Gosser	Research Assistant Professor	The City College of the City University of New York
Zachary	Greenberg	Director of Engineering	AgTechLogic
Richard	Greene	CEO	RGA
Adam	Griffiths	CEO	Imbueit
Mirta	Grifman	VP Clinical Development and Innovation	Biosplice Therapeutics
Josh	Groleau	CEO	Pecos Wind Power
Kristin	Gross	Founder	Navdee
David	Grund	Founder	refle-X-tions
Amadou	Gueye	CEO	TANIM
Joshua	Gustafson	Student Associate	Sorenson Impact Institute
Chris	Hagerup	Director	Matchbox
Mehran	Hamidi	CEO	Protected Wellness
Tiffany	Hamilton	CEO	Victor Wear LLC
Steven	Hamrick	Senior Attorney	Trow & Rahal, P.C.
Malcolm	Handelsman	Executive Director	Do It Right/Active Angels Network
Michael	Hanson	Growth Strategy Consultant	Optimum Dynamics LLC
Tawanna	Hardy-Ventress	Small Business Coach	GoBe
Thrine	Harpring	Accountant, Bookkeeper	Cover Your Accounts, LLC
Chris	Harrises	President	Technical Solutions, Inc.
Marcia	Hart	CEO / Co-Founder	Djit Medtech, Inc.
Qaizar	Hassonjee	Managing Partner	Angel Star Ventures
Melissa	Hawkins	Associate Chair, Dept of Health Studies	American University
Phil	Heifetz	Principal	Narberth Ventures
Teresa	Henning	Director	moneymasternow
Teresa	Henry	Sr Dir Scientific Operations & CMC	Sequoia Biotech Consulting
Browning	Herbert	Managing Director	Ringbolt Capital
Lucas	Hewitt	Partner	Utility Warehouse
Ben	Hickey	Tenant Advisory	Lincoln Property Company
David	Hildebrandt	President	Sel Technologies Inc
Elena	Hinderliter	Entrepreneur	
CJ	Hinshaw	Investor	Bootstrap Venture Partners
Houda	Hippler	CEO	Hbc engineering
David	Hitt	VP	Alertus
Jesse	Hollander	CEO	Teleperson
Alyse	Holstein	CEO	HPG Partners, LLC
Jeff	Hone	CEO	Thunder Biotech
Sunhee	Hong	Managing Partner	Linkorus
Jennifer	Hotai	Founder	Plover Animation
Darnley	Howard	President	Advansa International
John	Hubert	Acting CEO	Alertgy Inc. .
Braxton	Huff	Product Designer	FlutterPads
Mike	Huska	CTO	Vistra Business Solutions
Paul	Iacovacci	CIO	Enascor Capital
Cody	Isabel	CEO and Founder	Mind, Brain, Body Lab
Dave	Izuka	Venture Accelerator	Venture Acceleration and Incubation Services
Mahari	Jackson	Analyst	KLS Alliance
Richard	Jacobson	General Counsel	Eatmii
Vineet	Jain	Partner	Wild Tree Ventures
Jyoti	Jaiswal	CEO	OMSutra
Ivan	Jaubert	Director of Entrepreneurship	SynBioBeta
Emma	Javelin	Founder and Head of Marketing	The Social Frequency
Jacob	Jensen	Associate	Wasatch Equity Partners
Joy	Jones	CEO	joyjonesllc
Santosh	Joseph	Founder, CEO	Hospitality Leadership & Marketing
Thomas	Jueng	Sr. Managing Director	Samsung Ventures America
Rabiya	Kader	Patent Attorney	Sanofi
Alan	Kadish	CEO	InvestorMatch.ai LLC
Ben	Katz	Managing Partner	Sentinel VC
Ron	Kazel	Managing Member	Kalliam Capital LLC
Jim	Kean	CEO	Molecular You
Joe	Kessler	Managing Partner	Next-Stage Development Group
Gene	Kim	Founder	DragonStartups
Kimberly	King	Investment Partner	Impactx
Ted	Kirsch	CEO	CaperRX, Inc.

Danil	Kislinskiy	GP	GGW Ventures
Ted	Koblick	Vice President	Net-AV
Wes	Koch	Investor Analyst	Keiretsu Forum Southern Califo
Martin	Koev	Manager	Koev Brothers
Ellen	Koh	Director of Marketing	Raycom Communications Solutions, Inc.
Danielle	Kollmann	Company Owner	Handelsagentur OREL
Velibor	Koprivica	Chief Strategy Officer	Enfinia Growth Partners
Telcy Justice	Koudedikissa	Founder/CEO	Smart GiftWise
Nick	Kovacic	Partner	DealMaker.tech
Victoria	Kozyreva	Venture Associate	Go Global World
Tanya	Krechyk	VP of Partnerships in Europe	Honeycomb Software
Jason	Kreisberg	Associate Director	Sanford Labs
M.D.	Kull	Founder and President	Amplifi Consulting and Executive Strategy
Sachin	Kumar	CTO	Travelory Inc
Brenda	Kurnik	Angel Investor	Robinhood ventures
Sapthagiri	L	BE ECE	SNS college of technology
Eduardo	Laborda	Director IO	Calibr - Skaggs
Dennis	LaPorte	President/Founder	BioScientia Consulting
First Name	Last Name	Job Title	Company
Maurice	Lauriano	Equity Warrior and Government Sales Strategist	Got Goals LLC
Veronica	Lawrence	CEO	Inclusivity EQ
William	Le	VP, Global Operations	ImaginAb Inc.
Ines	LeBow	CE)/Founder	Enterprise Transformation Solutions, LLC
Jack	Lee	Managing Director	Marketing Integration
Steven	Lehat	Director	Colton Alexander
Kevin	Lerner	Presentation Specialist / Pitch Deck Pro	The Presentation Team
Zhichao	Li	Angel Investor	Individual Investor
Edward	Lin	Executive Director	Home Helpers Home Care of Hanover MD
Rob	Link	Founder & CEO	TCA
Stephan	Little	Managing Partner	Zero Limits Ventures / Zero Limits Capital
Eugene	Livshits	President	EHL Pharma LLC
Benn	Llewellyn	CEO	Trafficsamsllc
Kaylin	Lo	Entrepreneur Associate	Keiretsu Forum
Cheryl	Lohman	CEO	Kyst Box Inc.
Danielle	Lopez-Carter	Project Manager	Young Thagard
Harlan	Lovestone	Artist	Art Haus Project
Matthew	Lucci	CEO	Runatek
Emily	Lunger	Director of Marketing and Business Development	NetVest
George	Luniv	Founder / Director / System Eng.	Alomega Inc. Power from On High (R)
Jackie	Luo	Principal	BAM Advisory LLC
James	Lynch	CEO	Vision Solutions AR
Lily	M	Content Marketer	Socialmedialily
Amrita	Madabushi	Founder	EmpowerBio
Pinaki	Majhi	Owner	Unicus Pharmaceuticals
Patrick	Manning	CEO	Diagnostox
Michelle	Mantia	Controller	Intrommune Therapeutics
Bryan	Margaca	Co-Founder	Freebird Rides
Harrison	Marick	Chief Strategy Officer	Tiber Solutions
Harsh	Marketer	Business Development Executive	Adommerce
Kym	Martin	Founder & Communication Coach	Cohesive Insights
Nancy	Martinez	PO	Propio
John	Mason	CEO	Eatmii
Ina	Masten	Fractional CFO/Trusted Accounting Advisor	Masten Solutions LLC
Mike	Mausteller	President	BBP
Aisha	Mccain	CEO	Casual Recovery Enterprises inc
Tracy	Mccullom	CEO	The Nolan Group
Carl	McRae	Founder	Valiant Games
Welleminah	Mdinisa	Chief Investment Officer	GoGetta Limited
Patricia	Medina	Marketing Director	Aztex Trading SA de CV
Don	Megrath	Managing Director / Executive Director	VectorPoint Ventures / Investors Circle Angel Group
Maha	Mehanna, PhD	Vice-President of Business Development & Portfolio	XGen Pharmaceuticals DJB, Inc.
Robert	Mendralla	President, Investments	RM Enterprises
Lily	Meng	CEO	CoCarting
Andrey	Mikhailchuk	CEO	Craftus, LLC
Tomas	Milar	CEO/ Founder	Eqvista
Gabriel	Milfort	Senior Regional Manager	Primerica Financial Services
Randi	Miller	President	Venturesq LLC
Mohammad	Millwala	CEO	DM Clinical Research
Joseph	Mindak	Connector in Chief	The Connective
Joseph O.	Mjomba	CEO	Fundi Link
Charles	Mobbs	Founder and CEO	Gilga-Med, Inc.
Mohammad	Mohammad	Associate	Rev1 Ventures
Pouya	Monfared	CEO	Negó
Abu	Moniruzzaman	CEO	MindStaQ
John	Morgan	Managing Principal	Morgan Global LLC
Tina	Moriarty	Ops Manager	Malloy Industries
Lauris	Morics	Co-Founder	TaskTera

Roy	Morris	Partner	STI
Mitra	Mosharraf	CEO	Engimata
Vuyile	Mthethwa	Founder	Nyambose Corporation PTY
Kevin	Mullenex	CEO & CO-Founder	iotaBEAM, Inc.
Maureen	Mulvihill	President & CEO	Actuated Medical Inc
Eileen	Murphy	Network Marketing	Ultima
Charles	Nahabedian	CEO	VK Digital Health
Rajiv	Nayar	President	HTD Biosystems Inc
Matey	Nedkov	President	ICE
Gareth	Newman	CEO	Plausible Gaming
Christina	Nguyen	Student	UC Davis
Paul	Nolde	Managing Director	757 Angels
Michael	Norton	President	Axcess Instruments.com
Assumpta	Nwaigbo	IT Project Manager	Techtink Solutions Ltd
Esther Onefuwa	Oguns		Università di Macerata
Berta	Okenve Krohnert	Head of Biotech/ Health / Life Science Projects	Inspiralia
Lola	Omishore	PT	TheraMotive
Bob	Oros	President	Business Development Resources
Shoichi	Osawa	Sr. Director	Sony Semiconductor Solutions
Akshay	P	Student	Nil
Joseph	Park	CEO	Vividvista
Lucien	Parsons	Lead Catalyst	Operations Catalyst
Kajal	Patel	Broker/Owner	Open Doors Realty, LLC
Cayley	Pater	Founder & CEO	Made Trade
John	Paty	Principal	Geostrategic, LLC
Aaron	Pease	Managing Member & Principal Attorney	Highbridge Law Firm, PLLC
Mhiel	Peralta	Iro	Royal belle equity
Tom	Perkins	Director	BVI
Jace	Perry	Analyst	Wasatch Equity Partners
Brad	Phillips	Director, Emerging Company Solutions	PwC
Nehal	Phophalia	Sales Manager	Scalar Tech Media
Caroline	Pinkney	Investor	Mitsui Global Investment
Marius	Pintea	BDM	Moonshot International
Jae	Pizarro	CCO	Pro Docs Plus
George	Platt	CEO	ESI
William	Podd	President	Landmark Family Office
Tatyana	Pokrovskaya	Producer-Director CEO	www.cinelure.com
Kris	Polineni	CEO	Serebrum Corp
Joel	Price	VP of Product Innovation	Core Source Technologies
Elizabeth	Pyle	ICAP Life Science Business Mentor	George Mason University
Nadra	Qamaria	Founder & Lead Creative	The Nadra Agency
George	Radmilovic	COO	Zimmersive4u
Rajesh	Rajendran	Co-Founder	Ensure Digital
Rianna	Ramrick	Virtual Assistant	Virtual Rianna
Al Ameen	Rasheed	Head of Product Design	WHIZ OPTIMUM ARTIFICIAL INTELLIGENCE
Joe	Reddix	President and CEO	The Reddix Group
Damoder	Reddy	Investor	Chemical Angels
Courtney	Redman	Executive Assistant	Holmes Smith Consulting
Ronald	Redmer	Managing Partner	R-Squared Capital Partners LLC
Anna	Regensburger	Owner, President	Security Self Storage
Paul	Reid	CEO	Celtic Biotech
Alexander	Reynolds	Talent Acquisition Partner	Hippogriff
John	Rezaiyan	Entrepreneur/Advisor/Mentor/Coach	3E Consulting
Victor	Rhoder	VP of Channels and Strategic Partnerships	AtWork Systems LLC
John	Ricci	MD	US ANGELS
Gary	Robinson	CEO Founder	PhaseDesign Research
Alexander	Roeschmann	Junior Analyst	Vorsprung Climate
Bobbjean	Rose	Community Liaison	Walk with thee
Robert	Rosenberg	President	S M C
Larry	Rosenfeld	Investor	McLean Partners LLC
Darlene	Ross	Agent	De
Nader	S	Founder	genex
Amir	Saberi	Director	Vita
Ehsan	Salimi	ML Scientist	Amazon
Hans	Sanchez Nagel	Account Manager	Inspiralia
Bill	Sareen	Managing Partner	Asta LLC
Stefan	Scherer	CEO	3tBiosciences.com
Alan	Schlaifer	Chairman	Wharton DC Innovation Summit
Michael	Schwartz	Vice President	J.P. Morgan
Katerina	Serafimova	Management Consultant	in transition
Mario	Shaffer	Self	Self
Mitesh	Shah	CEO	www.video-animation-service.com
Katherine	Sharadin	CEO	UbiDX
Shian-Jiun	Shih	CEO	Cellentiabio
Sunny	Shrestha	Founder	madebysunnypradhan
Evan	Shubin	President and Director of Investments	Candlelight Partners LLC
Miguel	Sibayan	VC Fellow	Mighty Capital

Richard	Sidwell	CSO	Societal CDMO
Megan	Silvestro	Director of Business Development	JALEX Medical
Cal	Simmons	Chairman,	Tiger21 DC Chapter
Gary	Simon	Chairman	CleanStart, Inc.
Mike	Simpson	CEO	Omura
Sanjee	Singla	VP Product Development and Operations	Saltenna LLC
Mike	Smith	CEO	MSBD and Greensmith PR
Igor	Smolyaninov	Founder and CTO	Saltenna
Nathan	Snook	Developer	Snook Digital
Tom	Solitario	Principal	Tom, Inc.
Yuvraj	Sonal	BOD	Taxanomic
Frank	Song	Founder	Riverside Consulting
Martin	Sørnes	Founder, Audiologist, Inventor	HEAROLL MEDICAL INC
Kalyan	Sriramaneni	CEO	INDESTRL
David	Stamps	CEO- Office Hours Resident at The Kennedy Center	Spoken World Entertainment
Ernest	Stern	Partner	Culhane PLLC
Frank	Stitely	CEO	Clarity Practice Management PLLC
Julia	Stock	Director	Be Astute Ltd
Henry	Stoever	Principal	Brentwood Advisory Group
Rachael	Stott	CEO	Refraction
Christopher	Strong	Producer	Illumination Cinema
Dilip	Sundaram	Investment Partner	Vidavoo
Ning	Sung	Investor	Sand Hill Angels
Tom	Swanson	President	TJSwanson Co.
George	Swinson	Software Developer	Wik AI
William	Szura	Founder	Neufaze
Darryle	Taylor	Business Manager	CollabTech-GSU
Mahwish	Tazeem	Lawyer	n/A
Ryan	Tilley	Director: Strategy & Innovation	IHMC
Nicolas	Topuz	Investment Analyst	Supernova Invest
Colby	Tracy	CFO	Wasatch Equity Partners
Leo	Trautwein	Chief Commercial Officer	Know Labs
Cary	Truelick	Partner / Producer	True Story Films
Antoine	V	Founder Ceo	Analyticxpress
Christopher	Valadez	CEO	Thermatome
Simon	Valentine	CCO	BasePair Inc
Laarni	Valledo	Business Development Manager	Management Analytics
Carol	Van Cleef	CEO	Luminous Group/Comptegrity
Karl	Varner	Managing Director	Varner International
Chris	Veator	Investor	Self Employed
Roy	Vella	Managing Director	Vella Ventures
Alex	Veselov	Director	Flutter Pads
Marina	Vieva	Founder	FemiSpace
Jim	Voeller	Patent Attorney	Maier & Maier
Tom	Vogelsong	Angel Investor and Startup Scout	K2X Technology and Life Science
S. Eric	Wachtel	CEO	SmartMD Systems
Jordan	Wahbeh	Managing Partner	SV Venture Group
Ian	Waite	College Student	Lynn University
Michael	Walsh	CEO	WorldCitizen.One
Dave	Walton	Director	Alertgy
Gerald	Wasige	Founder	Tuko Digital
Barry	Weinbaum	Financial Services Professional	New York Life
Irving	Weinberg	President	Weinberg Medical Physics, Inc.
Robert	Weissman	President	Suvarna Partners LLC
Mark	Whittaker	President	Scientific Research Consortium, Inc.
Laurie	Wiggins	CEO	Byond
Albert	Williams	CEO	Perkforce
James	Wilson	Chairman	Zea Biosciences
Bo	Wu	CFO	WH-Power Inc.
Yi	Yang	Managing Partner	WaterStar Capital
A J	Yarmie	Principal	Janan BizDev
Hanqing	Ye	Founder	Beyond Biotech LLC
John	Yoakum	Principal Expert	Adept Opinion
Randell	Young	General Partner	Cache Creek Partners
Paola	Zaragoza Cardenales	CEO	Zaragoza Cardenales
Levi Karl	Zayas	Senior Consultant	Serial Disruptors
Raymond	Zoeller	Investor & Advisor	K2X Technology and Life Science Inc.
Juliet	Zon	Life Sciences Consultant	Johns Hopkins University

# THANK YOU TO OUR PREP TEAM



**LAURA HILL**  
SVP  
Equifi



**INES LEBOW**  
CEO  
Enterprise Transformation  
Solutions



**MARISSA LEVIN**  
CEO  
Successful Culture  
International



**BOB LONDON**  
CEO  
Chief Listening Officers



**JET LU**  
Customer Solutions  
Amazon Web Services



**JACKIE LUO**  
Founder  
BAM Advisory




**MICHELLE MILLER**  
Founder  
MRM Consulting



**JOHN MORGAN**  
General Partner  
Morgan Global



**EVAN SHUBIN**  
Pres. and Founder  
Results.now, Inc. and  
Candlelight Partners



**MALI PHONPADITH**  
CEO  
SOAR Community  
Network



**MICHAEL RIEMER**  
CEO & Board Member  
Vocinity

# SPONSORS



## Angels + Life.Sci Investors





# WANT TO PRESENT OR SPONSOR AT OUR VIRTUAL EVENTS?

Email Skylar Rallison at  
[srallison@opus8.com](mailto:srallison@opus8.com)  
for more information

## 2024 Virtual Calendar

---

June 27

July 25

Aug. 29

---

Oct. 31

Nov. 21

Dec. 19

---

# REGISTER FOR OUR UPCOMING EVENTS

June 13

In-Person Pitch



June 27

Virtual Pitch



June 2

Sunday Brunch



June 6

Wind Harvest Virtual



# CONNECT WITH US!





## CUSTOM PRIVATE INVESTOR MEETING

### Overview

- Opus8 manages one of the world's largest investor communities with 4,000+ HNW/UHNW private investors, angels, family offices, investment groups, and small institutional investors.
- We have become a reliable curator and source of high-quality investment opportunities for this community.
- The Client is the exclusive host of these private investor meetings. No other competing or external entities in the meeting.
- Opus8 will screen a minimum of 20+ pre-qualified attendees for the event. The general attendee mix is 75% investors and 25% COIs (Centers of Influence).
- Attendee/RSVP lists with contact information and LinkedIn profiles and other data will be provided to the Client before and after the event.

### Our 9-Step Process

1. Review investment materials and determine key investment considerations.
2. Develop a list of potential investors.
3. Create a "teaser invitation" and send it to investor candidates along with an executive summary
4. Confirm and vet RSVPs
5. Answer any questions or info requests pre-event.
6. Triple confirm all RSVPs via email and calendar invitations.
7. Host the private investor event and follow-up with attendees.
8. Introduce any RSVPs who did not attend to management.
9. Assist in following up with any and all investor prospects post-event.

**Check out the full brochure with all information here:**

